RESMED INC (RMD)
Data as of , from SEC Form 4 filings.
See up to 3 months of RMD. The 7-day demo opens the 1M and 3M ranges and puts RMD on your watchlist.
Start 7-day demoLatest RMD insider trades
About RESMED INC (RMD)
ResMed is one of the largest respiratory care device companies globally, primarily developing and supplying flow generators, masks, and accessories for the treatment of sleep apnea. Increasing diagnosis of sleep apnea, combined with aging populations and increasing prevalence of obesity, is resulting in a structurally growing market. The company earns roughly two-thirds of its revenue in the Americas and the balance across other regions dominated by Europe, Japan, and Australia. Recent developments and acquisitions have focused on digital health as ResMed is aiming to differentiate itself through the provision of clinical data for use by the patient, medical care advisor, and payer in the out-of-hospital setting.
- SAN DIEGO, CA
- 11,370
- 1995
- XNYS
RMD Form 4 activity by transaction type, last 90 days
| Form 4 transaction type | Transactions | Shares | Total value |
|---|---|---|---|
| Open-market sale | 5 | 23,943 | $5.29M |
| Grant or award | 3 | 18,763 | |
| Option exercise | 6 | 29,946 |
Dollar totals cover purchases and sales only (codes P and S). Grants, option exercises, gifts and tax withholding are counted in shares, because none of them is a trade at a market price.
RMD insider transactions (Form 4)
48108 Form 4 filings on record, the earliest from Oct 2, 2024, newest first. Filing history page 1 of 3.
| Date | Insider | Transaction | Security | Shares | Price | Value |
|---|---|---|---|---|---|---|
| Michael J. Farrell - Officer | Option exercise | ResMed Common Stock | 4,991 | $146.34 | $730K | |
| Michael J. Farrell - Officer | Open-market sale | ResMed Common Stock | 4,991 | $226.33 footnote F2 | $1.13M | |
| Michael J. Farrell - Officer | Option exercise | ResMed Common Stock Options | 4,991 | $0.00 | - | |
| ||||||
| Justin Leong - Officer | Grant or award | ResMed Common Stock | 6,461 | $0.00 | - | |
 Michael J. Rider - Officer | Grant or award | ResMed Common Stock | 3,230 | $0.00 | - | |
| Aaron Bloomer - Officer | Grant or award | ResMed Common Stock | 9,072 | $0.00 | - | |
| Michael J. Farrell - Officer | Option exercise | ResMed Common Stock | 4,991 | $146.34 | $730K | |
| Michael J. Farrell - Officer | Open-market sale | ResMed Common Stock | 4,991 | $222.44 footnote F2 | $1.11M | |
| Michael J. Farrell - Officer | Option exercise | ResMed Common Stock Options | 4,991 | $0.00 | - | |
| ||||||
| Peter C. Farrell - Director | Open-market sale | ResMed Common Stock | 970 | $234.73 | $228K | |
| Michael J. Farrell - Officer | Option exercise | ResMed Common Stock | 4,991 | $146.34 | $730K | |
| Michael J. Farrell - Officer | Open-market sale | ResMed Common Stock | 4,991 | $205.69 footnote F2 | $1.03M | |
| Michael J. Farrell - Officer | Option exercise | ResMed Common Stock Options | 4,991 | $0.00 | - | |
| ||||||
| Peter C. Farrell - Director | Open-market sale | ResMed Common Stock | 8,000 | $225.00 | $1.80M | |
| Michael J. Farrell - Officer | Option exercise | ResMed Common Stock | 4,991 | $146.34 | $730K | |
| Michael J. Farrell - Officer | Open-market sale | ResMed Common Stock | 4,991 | $218.55 footnote F2 | $1.09M | |
| Michael J. Farrell - Officer | Option exercise | ResMed Common Stock Options | 4,991 | $0.00 | - | |
| ||||||
| Michael J. Farrell - Officer | Option exercise | ResMed Common Stock Options | 4,991 | $0.00 | - | |
| Michael J. Farrell - Officer | Option exercise | ResMed Common Stock | 4,991 | $146.34 | $730K | |
| Michael J. Farrell - Officer | Open-market sale | ResMed Common Stock | 4,991 | $193.96 footnote F2 | $968K | |
| ||||||
| Michael J. Rider - Officer | Tax withholding / forfeiture | ResMed Common Stock | 268.74 footnote F1 | $190.57 | $51K | |
| ||||||
| Michael J. Farrell - Officer | Option exercise | ResMed Common Stock | 4,991 | $146.34 | $730K | |
| Michael J. Farrell - Officer | Open-market sale | ResMed Common Stock | 4,991 | $207.82 footnote F2 | $1.04M | |
| Michael J. Farrell - Officer | Option exercise | ResMed Common Stock Options | 4,991 | $0.00 | - | |
| ||||||
| Michael J. Farrell - Officer | Option exercise | ResMed Common Stock | 4,991 | $146.34 | $730K | |
| Michael J. Farrell - Officer | Open-market sale | ResMed Common Stock | 4,991 | $225.50 footnote F2 | $1.13M | |
| Michael J. Farrell - Officer | Option exercise | ResMed Common Stock Options | 4,991 | $0.00 | - | |
| ||||||
 Brett Sandercock - Officer | Open-market sale | ResMed Common Stock | 1,000 | $224.31 | $224K | |
| Peter C. Farrell - Director | Open-market sale | ResMed Common Stock | 2,000 | $225.00 | $450K | |
| Michael J. Farrell - Officer | Open-market sale | ResMed Common Stock | 4,991 | $251.03 footnote F2 | $1.25M | |
| Michael J. Farrell - Officer | Option exercise | ResMed Common Stock Options | 4,991 | $0.00 | - | |
| Michael J. Farrell - Officer | Option exercise | ResMed Common Stock | 4,991 | $146.34 | $730K | |
| ||||||
| Peter C. Farrell - Director | Open-market sale | ResMed Common Stock | 2,000 | $260.22 | $520K | |
| Brett Sandercock - Officer | Open-market sale | ResMed Common Stock | 1,000 | $254.30 | $254K | |
| Michael J. Farrell - Officer | Option exercise | ResMed Common Stock | 4,991 | $146.34 | $730K | |
| Michael J. Farrell - Officer | Open-market sale | ResMed Common Stock | 4,991 | $273.78 footnote F2 | $1.37M | |
| Michael J. Farrell - Officer | Option exercise | ResMed Common Stock Options | 4,991 | $0.00 | - | |
| ||||||
| Peter C. Farrell - Director | Open-market sale | ResMed Common Stock | 2,000 | $251.31 | $503K | |
| Michael J. Rider - Officer | Open-market sale | ResMed Common Stock | 50 | $260.00 | $13K | |
| Brett Sandercock - Officer | Open-market sale | ResMed Common Stock | 1,000 | $257.03 | $257K | |
| Peter C. Farrell - Director | Open-market sale | ResMed Common Stock | 2,000 | $248.83 | $498K | |
| Michael J. Farrell - Officer | Option exercise | ResMed Common Stock | 4,991 | $146.34 | $730K | |
| Michael J. Farrell - Officer | Open-market sale | ResMed Common Stock | 4,991 | $248.46 footnote F2 | $1.24M | |
| Michael J. Farrell - Officer | Option exercise | ResMed Common Stock Options | 4,991 | $0.00 | - | |
| ||||||
| Brett Sandercock - Officer | Open-market sale | ResMed Common Stock | 1,000 | $241.75 | $242K | |
| Michael J. Rider - Officer | Open-market sale | ResMed Common Stock | 50 | $241.75 | $12K | |
| Michael J. Rider - Officer | Open-market sale | ResMed Common Stock | 50 | $244.16 | $12K | |
| Brett Sandercock - Officer | Open-market sale | ResMed Common Stock | 1,000 | $244.16 | $244K | |
Recent RMD Form 144 notices of proposed sale
3An insider files Form 144 before selling restricted or control stock. It announces a planned sale. If the sale goes ahead, it shows up later on a Form 4.
| Filed | Filer | Relationship | Shares | Market value | Notice |
|---|---|---|---|---|---|
| Farrell Michael J. | Officer, Director | 4,991 | $1.13M | View on EDGAR | |
| Farrell Michael J. | Officer, Director | 4,991 |
RMD insider trading FAQ
What is the latest insider trade for RMD?
RESMED INC (RMD) had 9 insider filings in the last 90 days, with the most recent on 2026-10-08. The full record for RMD runs to 108 Form 4 filings, the earliest from 2024-10-02. InsiderAlpha adds new Form 4, Form 144 and 8-K filings as they arrive from SEC EDGAR.
How many insiders are buying RMD stock?
No insider purchases of RMD were filed in the last 90 days.
How many insiders are selling RMD stock?
5 insider sales of RMD were filed in the last 90 days, totaling $5.29M.
Where can I see RMD SEC filings (Form 4, 10-K, 10-Q, 8-K)?
This page collects RMD Form 4 insider transactions, Form 144 sale notices and 8-K filings in one place. Annual 10-K and quarterly 10-Q reports live on the company's SEC EDGAR page.
More Health Care companies with insider activity
Recent insider filings
10The EDGAR links open each original Form 4, so you can check any number on this page against the filing it came from.
- - Michael J. Farrell view on EDGAR
- - Michael J. Farrell view on EDGAR
- - Justin Leong view on EDGAR
- - Michael J. Rider view on EDGAR
- - Aaron Bloomer view on EDGAR
- - Michael J. Farrell view on EDGAR
- - Peter C. Farrell view on EDGAR
- - Michael J. Farrell view on EDGAR
- - Peter C. Farrell view on EDGAR
Related companies with recent insider activity
Learn more
- Insider selling: signal or noise?
- Why most insider sales are routine, and the few patterns worth a second look.
- Form 144 vs Form 4
- A Form 144 announces a planned sale; the Form 4 reports it after it happens.
- Insider activity in Health Care
- Where RMD's peers are being bought and sold.
- Every recent Form 4
- The market-wide feed, updated as filings arrive from SEC EDGAR.
Follow RMD with a 7-day demo
- RMD on your watchlist
- Every RMD Form 4 filing on record
- Up to 3 months of RMD price history
- The daily trading plan of ranked insider buys, on a delay, with the plan archive
